Background: Within the development and approval of several new direct-acting antivirals (DAA) against hepatitis C virus (HCV), a new era of hepatitis C therapy has begun. Even more treatment options are likely to become available during the next 1-2 years. Methods: A summary of the current phase II and III trials investigating DAA and a review of the recent HCV guidelines was conducted. Results: With the development of new potent DAA and the approval of different DAA combinations, cure rates of HCV infection of >90% are achievable for almost all HCV genotypes and stages of liver disease. Currently available DAA target different steps in the HCV replication cycle, in particular the NS3/4A protease, the NS5B polymerase, and the NS5A replication complex. Treatment duration varies between 8 and 24 weeks depending on the stage of fibrosis, prior treatment, HCV viral load, and HCV genotype. Ribavirin is required only for some treatment regimens and may be particularly beneficial in patients with cirrhosis. DAA resistance influences treatment outcome only marginally; thus, drug resistance testing is not routinely recommended before treatment. In the case of treatment failure, however, resistance testing should be performed before re-treatment with other DAA is initiated. Conclusion: With the new, almost side effect-free DAA treatment options chronic HCV infection became a curable disease. The clinical benefit of DAA combination therapies in patients with advanced cirrhosis and the effects on incidence rates of hepatocellular carcinoma remain to be determined.

Keywords:
Hepatitis C, Direct-acting antivirals, DAA, Cirrhosis, Drug resistance
1.
Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, Wang CH, Chen WJ, Chen CJ; R.E.V.E.A.L.-HCV Study Group: Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012;206:469-477.
2.
Maasoumy B, Wedemeyer H: Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012;26:401-412.
3.
Razavi H, Waked I, Sarrazin C, et al: The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014;21(suppl 1):34-59.
4.
van der Meer AJ, Veldt BJ, Feld JJ, et al: Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-2593.
5.
Sarrazin C, Berg T, Ross RS, et al: Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection (Article in German). Z Gastroenterol 2010;48:289-351.
6.
Wedemeyer H, Duberg AS, Buti M, et al: Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014;21(suppl 1):60-89.
7.
Heidrich B, Wiegand SB, Buggisch P, et al: Treatment of naive patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA. PloS One 2014;9:e108751.
8.
Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R: Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-113.
9.
Hinrichsen H, Benhamou Y, Wedemeyer H, et al: Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004;127:1347-1355.
10.
Tomei L, Failla C, Santolini E, De Francesco R, La Monica N: NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol 1993;67:4017-4026.
11.
Jacobson IM, McHutchison JG, Dusheiko G, et al: Telaprevir for previously untreated chronic hepatitis C virus infection. New Engl J Med 2011;364:2405-2416.
12.
Poordad F, McCone J Jr, Bacon BR, et al: Boceprevir for untreated chronic HCV genotype 1 infection. New Engl J Med 2011;364:1195-1206.
13.
www.accessdata.fda.gov/drugsatfda_docs/label/2012/ 201917s007lbl.pdf.
14.
Sarrazin C, Berg T, Cornberg M, et al: Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C (Article in German). Z Gastroenterol 2012;50:57-72.
15.
Sherman KE, Flamm SL, Afdhal NH, et al: Response-guided telaprevir combination treatment for hepatitis C virus infection. New Engl J Med 2011;365:1014-1024.
16.
Jacobson IM, Dore GJ, Foster GR, et al: Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014;384:403-413.
17.
Manns M, Marcellin P, Poordad F, et al: Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014;384:414-426.
18.
Jensen DM O'Leary J, Pockros P, et al.; for the HCV-TARGET Study Group: Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real-World Experience in a Diverse, Longitudinal Observational Cohort. 65th Annual Meeting of the American Association for the Study of Liver Diseases. November 7-11, 2014, Boston, USA. Abstract 45. www.natap.org/2014/AASLD/AASLD_10.htm.
19.
Lok AS, Gardiner DF, Lawitz E, et al: Preliminary study of two antiviral agents for hepatitis C genotype 1. New Engl J Med 2012;366:216-224.
20.
Gao M, Nettles RE, Belema M, et al: Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010;465:96-100.
21.
Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al: Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New Engl J Med 2014;370:211-221.
22.
Manns M, Pol S, Jacobson IM, et al: All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014;384:1597-1605.
23.
Zeuzem S, Hezode C, Bronowicki J-P, et al: Daclatasvir in Combination with Simeprevir with or without Ribavirin for Hepatitis C Virus Genotype 1 Infection. 21st Conference on Retroviruses and Opportunistic Infections. March 3-6, 2014. Boston, USA. www.natap.org/2014/CROI/croi_09.htm.
24.
Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK: Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 2015;61:56-65.
25.
Jacobson IM, Gordon SC, Kowdley KV, et al: Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. New Engl J Med 2013;368:1867-1877.
26.
Zeuzem S, Dusheiko GM, Salupere R, et al: Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients with HCV Genotype 2 or 3: the VALENCE trial. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013). November 1-5, 2013. Washington, DC, USA. www.natap.org/2013/AASLD/AASLD_15.htm.
27.
Lawitz E, Sulkowski MS, Ghalib R, et al: Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756-1765.
28.
Dieterich D, Bacon BR, Flamm S, et al.: Evaluation of Sofosbuvir and Simeprevir-Based Regimens in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population. 65th Annual Meeting of the American Association for the Study of Liver Diseases. November 7-11, 2014. Boston, USA. Abstract 46. www.natap.org/2014/AASLD/AASLD_09.htm.
29.
Afdhal N, Zeuzem S, Kwo P, et al: Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New Engl J Med 2014;370:1889-1898.
30.
Afdhal N, Reddy KR, Nelson DR, et al: Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. New Engl J Med 2014;370:1483-1493.
31.
Kowdley KV, Gordon SC, Reddy KR, et al: Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. New Engl J Med 2014;370:1879-1888.
32.
Bourlière Sulkowski MS, Omata M, et al: Integrated Safety and Efficacy Analysis of >500 Patients with Compensated Cirrhosis Treated with Ledipasvir/ Sofosbuvir with or without Ribavirin. 65th Annual Meeting of the American Association for the Study of Liver Diseases. November 7-11, 2014. Boston, USA. Abstract 82.
33.
Feld JJ, Kowdley KV, Coakley E, et al: Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. New Engl J Med 2014;370:1594-1603.
34.
Ferenci P, Bernstein D, Lalezari J, et al: ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. New Engl J Med 2014;370:1983-1992.
35.
Poordad F, Hezode C, Trinh R, et al: ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. New Engl J Med 2014;370:1973-1982.
36.
Zeuzem S, Jacobson IM, Baykal T, et al: Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. New Engl J Med 2014;370:1604-1614.
37.
Lawitz E, Mangia A, Wyles D, et al: Sofosbuvir for previously untreated chronic hepatitis C infection. New Engl J Med 2013;368:1878-1887.
38.
Zeuzem S, Dusheiko GM, Salupere R, et al: Sofosbuvir and ribavirin in HCV genotypes 2 and 3. New Engl J Med 2014;370:1993-2001.
39.
Nelson DR, Cooper JN, Lalezari JP, et al: All-Oral 12-Week Combination Treatment with Daclatasvir and Sofosbuvir in Patients Infected with HCV Genotype 3: ALLY-3 Phase 3 Study. 65th Annual Meeting of the American Association for the Study of Liver Diseases. November 7-11, 2014. Boston, USA. Abstract LB-3. www.natap.org/2015/EASL/EASL_73.htm.
40.
Gane EJ, Hyland HR, An D, et al: Sofosbuvir/Ledipasvir Fixed Dose Combination Is Safe and Effective in Difficult-to-Treat Populations Including Genotype-3 Patients, Decompensated Genotype-1 Patients, and Genotype-1 Patients with Prior Sofosbuvir Treatment Experience. Program and abstracts of the 49th Annual Meeting of the European Association for the Study of the Liver. April 9-13, 2014. London, England. Abstract 06. J Hepatol 2014;60(suppl):S3-S4.
41.
Kapoor R, Kohli A, Sidharthan S et al: Treatment of Hepatitis C Genotype 4 with Ledipasvir and Sofosbuvir for 12 Weeks: Results of the SYNERGY Trial. 65th Annual Meeting of the American Association for the Study of Liver Diseases. November 7-11, 2014. Boston, USA. Abstract 240.
42.
Ruane PJ, Ain D, Meshrekey R, et al: Sofosbuvir plus Ribavirin, an Interferon-Free Regimen, in the Treatment of Treatment-Naive and Treatment-Experienced Patients with Chronic Genotype 4 HCV Infection. 49th Annual Meeting of the European Association for the Study of Liver Diseases. April 9-13, 2014. London, England. Abstract P1243.
43.
Pol S, Reddy KR, Baykal T, et al: Interferon-Free Regimens of Ombitasvir and ABT-450/r with or without Ribavirin in Patients with HCV Genotype 4 Infection: PEARL-I Study Results. 65th Annual Meeting of the American Association for the Study of Liver Diseases. November 7-11, 2014. Boston, USA. Abstract 1928.
44.
Cornberg M, Höner zu Siederdissen C, Maasoumy B, Solbach P, Manns MP, Wedemeyer H: Standard therapy of chronic hepatitis C virus infection; in Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H (eds): Hepatology. A Clinical Textbook, ed 6. Flying Publisher, 2015, pp 221-286.
© 2015 S. Karger GmbH, Freiburg
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.